INTRODUCTION
============

Many studies have shown that intensive control of blood glucose can significantly prevent diabetes-related chronic complications \[[@b1-kjim-2017-312],[@b2-kjim-2017-312]\]. These results are the theoretical basis for explaining the need for active blood glucose management to improve the clinical course of diabetic patients. However, recent studies have reported that overly rigorous blood glucose control may lead to a negative clinical course in patients \[[@b3-kjim-2017-312]-[@b5-kjim-2017-312]\]. Individualized blood glucose control goals that take into account the diverse clinical situations of diabetic patients are required \[[@b6-kjim-2017-312],[@b7-kjim-2017-312]\].

Lifestyle modification (LSM) is the first treatment for successful diabetes management. The effects of LSM on the clinical course of diabetes have been demonstrated in several studies \[[@b8-kjim-2017-312],[@b9-kjim-2017-312]\]. However, due to the pathophysiological nature of type 2 diabetes mellitus (T2DM), where β-cell function is gradually diminishing, it is difficult to maintain adequate blood glucose control with LSM alone \[[@b10-kjim-2017-312]\]. Therefore, in many patients, medication should be administered from the beginning of the treatment for proper blood glucose control.

This article was written to provide the rationale for the update of the position statement of the Korean Diabetes Association (KDA), and the contents of oral hypoglycemic agent monotherapy were described.

RECOMMENDATIONS
===============

Principles of initial management after diagnosis of type 2 diabetes mellitus
----------------------------------------------------------------------------

1.  1\. Active lifestyle modification and appropriate pharmacotherapy are needed from the initial diagnosis of diabetes \[A\].

2.  2\. An appropriate selection of pharmacotherapy should be made after considering the clinical characteristics of the patient and drug efficacy, side effects, mechanism of action, risk of hypoglycemia, effect on body weight, and patient preference and combined comorbidity \[E\].

Principles of treatment with antihyperglycemic agents
-----------------------------------------------------

1.  1\. Metformin is the preferred initial oral hypoglycemic agent \[A\].

2.  2\. If metformin is contraindicated or not well tolerated as the initial treatment, another class of hypoglycemic agent can be used depending on the clinical situation \[E\].

3.  3\. If monotherapy fails to achieve the glycemic target, combination therapy with a second agent with a different mechanism of action should be initiated \[A\].

METHODS
=======

Selection of topics, organization of the working group, and determination of methods
------------------------------------------------------------------------------------

In March 2017, the Clinical Practice Guideline (CPG) update was discussed at the Committee of Clinical Practice Guideline in the KDA. The committee decided to carry out an amendment in this revision that reflects the new diabetes medications. For this task, the committee formed a working group for revising the relevant content of the CPG. The guidelines were revised based on a systematic review of the newly published literature, along with the other national and international CPG contents. The details of this process are described in detail in other documents \[[@b11-kjim-2017-312]\].

Key question selection
----------------------

The task of the authors of the current article was evaluating the monotherapy of oral hypoglycemic agents for the working group. We have determined the key questions for revising the CPG according to the results of the discussion within the group. The first question is whether metformin is appropriate as a first-line choice for Korean patients with T2DM. The second question is how to choose the other first-line agent if metformin is not available. Finally, cardiovascular outcome with metformin or other monotherapy was determined to be the third key question.

Literature review
-----------------

For the purpose of revising the guidelines, various domestic and international guidelines have been referred to. We referred to the KDA guidelines and the Korea National Diabetes Program (KNDP) guidelines as domestic guidelines \[[@b12-kjim-2017-312],[@b13-kjim-2017-312]\] and referred to the guidelines of the American Diabetes Association (ADA), National Institute for Health and Care Excellence (NICE), International Diabetes Federation (IDF), Canadian Diabetes Association (CDA), and American Association of Clinical Endocrinologists and American College of Endocrinology (AACE) as foreign guidelines \[[@b14-kjim-2017-312]-[@b18-kjim-2017-312]\]. References that meet our key questions were adopted. In addition, a systematic review was conducted to obtain the latest evidence. A master database for systematic review was built by professional librarians and delivered to group members. The evidence levels of the articles in the database were evaluated according to individual reviews of the group members. Thereafter, a list of articles was prepared by mutual review and agreement of group members. A final list was established by independent committee members separate from the working group \[[@b11-kjim-2017-312]\].

Drafting, public hearing, and final approval of board of directors
------------------------------------------------------------------

The revised recommendations were circulated and evaluated by members of the committee other than the working group. Based on peer review, a draft CPG update was prepared. In July 2017, an initial draft was released at a public hearing. A final draft of the CPG update was prepared in accordance with the opinions gathered at the hearing. In August 2017, the final manuscript was approved by the Board of Directors, KDA.

COMMENTS ON RECOMMENDATIONS
===========================

Oral hypoglycemia agent as a monotherapy
----------------------------------------

For patients with T2DM who have not satisfactorily met therapeutic goals with LSM, a first-line oral hypoglycemic monotherapy should be administered. In monotherapy, approximately 0.5% to 1.5% of glycosylated hemoglobin (HbA1c) reduction is observed depending on the medication \[[@b19-kjim-2017-312]\]. Although there are some differences depending on the class, the maximal effect of the drug is usually observed 4 to 6 months after treatment \[[@b20-kjim-2017-312]\]. In general, the higher the patient's HbA1c, the greater the extent of HbA1c reduction with medication \[[@b19-kjim-2017-312]\]. Postprandial glucose control becomes more important for further improvement of HbA1c when blood glucose approaches the generally recommended level (less than 7.3% of HbA1c) \[[@b21-kjim-2017-312]\]. Some studies have shown that postprandial glucose is an independent risk factor for cardiovascular disease and death regardless of fasting glucose \[[@b22-kjim-2017-312],[@b23-kjim-2017-312]\]. However, the evidence for whether postprandial improvement of blood glucose is effective in improving additional cardiovascular disease outcomes is not yet clear.

Metformin as an initial treatment regimen
-----------------------------------------

Metformin is recommended as the drug for initial treatment in most diabetes-related CPGs worldwide \[[@b12-kjim-2017-312]-[@b18-kjim-2017-312]\]. Metformin is recommended as the first choice for patients with T2DM because of its excellent blood glucoselowering effect, relatively low adverse effects, long-term safety, low risk of hypoglycemia, and low weight gain. These recommendations are based on a cohort study in which metformin monotherapy in overweight T2DM patients was associated with more marked blood glucose-lowering effects and less weight gain and hypoglycemia compared to sulfonylurea or insulin monotherapy \[[@b24-kjim-2017-312]\]. Potential cardiovascular disease prevention effect is also included in the reason for choosing metformin as the initial treatment \[[@b24-kjim-2017-312],[@b25-kjim-2017-312]\]. However, the preventive effect of metformin on cardiovascular disease has yet to be ascertained.

In several subsequent observational studies and meta-analyses, there was evidence that metformin could be the drug of choice for initial treatment of diabetes patients compared to sulfonylurea, thiazolidinedione, and dipeptidyl peptidase 4 (DPP4) inhibitor, from the aspects of HbA1c reduction, side effects, weight gain, hypoglycemia, economic feasibility, and cardiovascular disease prevention \[[@b26-kjim-2017-312]-[@b29-kjim-2017-312]\]. In a prospective, multicenter clinical trial conducted in Korea, the effect of metformin monotherapy on HbA1c was similar to that of sulfonylurea or thiazolidinedione monotherapy \[[@b30-kjim-2017-312]\]. Based on the above evidence, we also recommend metformin as an initial first-line medication in this CPG.

Clinical situations such as hepatic failure, chronic kidney disease (caution in estimated glomerular filtration rate \[eGFR\] \< 60 mL/min/1.73 m2, contraindication in eGFR \< 30 mL/min/1.73 m2), severe infection, dehydration, and heart failure are contraindications of metformin use and it should be used with caution \[[@b14-kjim-2017-312],[@b17-kjim-2017-312]\]. Recently, a study suggesting that metformin use may be associated with vitamin B12 deficiency and anemia was published \[[@b31-kjim-2017-312]\]. Vitamin B12 measurements may be considered for metformin users with peripheral neuropathy or anemia.

Monotherapy using other oral hypoglycemic agents
------------------------------------------------

For patients who are contraindicated for metformin or who experience difficulties with metformin use, monotherapy of other hypoglycemic agents is considered as an initial treatment. Recently, as new drugs have been launched, various oral hypoglycemic agents have become available in clinical practice ([Table 1](#t1-kjim-2017-312){ref-type="table"}) \[[@b11-kjim-2017-312]\]. These drugs differ not only in their mechanism of action, but also in terms of cardiovascular disease prevention, side effects, contraindications, and price.

The DPP4 inhibitors have been widely used as a substitute for patients who have difficulty in using metformin monotherapy; these inhibitors are used because of their low incidence of side effects such as hypoglycemia. Recently, a meta-analysis has been reported by Korean researchers that suggests the effect of DPP4 inhibitors on Asians may be superior to other ethnicities \[[@b32-kjim-2017-312]\]. The effects of the DPP4 inhibitors on cardiovascular disease have been reported to be neutral according to multicenter, prospective, randomized controlled trials performed recently performed trials \[[@b33-kjim-2017-312]-[@b35-kjim-2017-312]\]. Although some DPP4 inhibitor have been reported to increase the risk of heart failure, systematic reviews have shown that the risk is not significant, and there is a slight difference in the risk of heart failure resulting from the use of DPP4 inhibitors \[[@b36-kjim-2017-312],[@b37-kjim-2017-312]\].

The use of sodium-glucose cotransporter 2 (SGLT2) inhibitors has recently led to a significant reduction in the risk of cardiovascular disease and mortality in patients with diabetes in multicenter, prospective, randomized controlled trials, and the frequency of use of these inhibitors is increasing in clinical settings \[[@b38-kjim-2017-312]-[@b41-kjim-2017-312]\]. However, due to possible side effects such as urogenital infection, dehydration, and hypotension, caution should be paid to its administration to some individuals such as the elderly and patients with chronic kidney disease \[[@b38-kjim-2017-312],[@b40-kjim-2017-312]\]. A recent multi-center, prospective, randomized controlled clinical trial has reported an increased risk of osteoporotic fractures and limb amputation associated with the use of this medication \[[@b41-kjim-2017-312]\]. Further research on the long-term safety of this drug is needed.

A wide variety of previously used drugs such as sulfonylurea, meglitinide, thiazolidinedione, and α-glucosidase inhibitor can also be used as an effective substitute for metformin after securing various evidence on efficacy and safety when using this monotherapy \[[@b29-kjim-2017-312],[@b42-kjim-2017-312]-[@b44-kjim-2017-312]\]. There is some evidence that thiazolidinedione may reduce the cardiovascular disease risk in patients with T2DM who have a high risk of macrovascular events \[[@b45-kjim-2017-312],[@b46-kjim-2017-312]\]. However, attention should be paid to increased edema, anemia, bone fracture, and heart failure risk in patients \[[@b46-kjim-2017-312]\]. α-Glucosidase inhibitor is an effective agent for postprandial glucose control \[[@b47-kjim-2017-312]-[@b49-kjim-2017-312]\]; however, side effects such as gastrointestinal trouble are frequent, and there is a lack of evidence for cardiovascular outcome \[[@b48-kjim-2017-312],[@b49-kjim-2017-312]\]. Sulfonylurea and meglitinide have an excellent blood glucoselowering effect. However, the cardiovascular benefit is not clear, and there is a risk of hypoglycemia \[[@b30-kjim-2017-312],[@b50-kjim-2017-312]\]. Recent studies in Korea have shown that hypoglycemia is closely related to adverse outcomes of patients \[[@b51-kjim-2017-312]-[@b54-kjim-2017-312]\]. Care should be taken with the use of drugs that are highly likely to cause hypoglycemia.

CONCLUSIONS
===========

Diabetes treatment should be individualized according to the patient's needs and preferences, and drugs should be selected taking into account the specific advantages and disadvantages of each drug \[[@b7-kjim-2017-312]\]. For a reasonable choice of medication, various clinical conditions should be considered including age, HbA1c, fasting and postprandial glucose, obesity or metabolic syndrome, insulin secretory capacity, risk of hypoglycemia, liver, cardiac or renal dysfunction, and patient preference.

Recently, new drugs have been introduced, and various clinical trials related to these drugs have been introduced. Different opinions on the selection of the initial treatment for patients with T2DM have been raised. We have yet to come to a complete conclusion as to which oral hypoglycemic agent should be the first choice for a particular patient, and which medication should be added next. In addition, we have not yet reached a consensus that it is reasonable to choose a particular medication for each of the various clinical situations. However, it is clinically more important to know what drug should control blood glucose, than what goal should blood glucose be controlled \[[@b17-kjim-2017-312]\]. Even if blood glucose and HbA1c levels do not reach the target, the prognosis of the patient can be significantly improved depending on the degree of improvement of these levels \[[@b1-kjim-2017-312]\].

Based on the literature review so far, metformin can be recommended as the first drug in Korean patients with T2DM. Metformin can be recommended from the variety of evidence accumulated to date. If metformin is difficult to use as an initial treatment, appropriate alternatives should be chosen considering the patient's individual circumstances. In addition to conventional drugs with which physicians have long-term experience such as sulfonylurea, thiazolidinedione, and α-glucosidase inhibitors, newer drugs such as the DPP4 inhibitors and the SGLT2 inhibitors also are indicated for monotherapy. If the goal of achieving glycemic control is not achieved by monotherapy, then combination therapy with different mechanisms of action should be initiated promptly.
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###### 

Oral antihyperglycemic agents for patients with type 2 diabetes mellitus used in Korea

                                                                                                                             Mechanism and common use                                                                                                                                                   Weight gain           Hypoglycemia^[a](#tfn1-kjim-2017-312){ref-type="table-fn"}^   HbA1c reduction, %^[a](#tfn1-kjim-2017-312){ref-type="table-fn"}^   Side effects                                                                                                       Caution
  -------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------- ------------------------------------------------------------- ------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Biguanide (metformin)                                                                                                      ↓ Hepatic glucose production                                                                                                                                               Neutral or decrease   No                                                            1.0--2.0                                                            GI side effects (anorexia, nausea, vomiting, diarrhea, cramping), vitamin B12 deficiency, lactic acidosis (rare)   Contraindication in severe hepatic or renal insufficiency (eGFR \< 30 mL/min/1.73 m^2^), severe infection, dehydration, heart failure. Major operation or iodine-contrast use within 48 hours
  Start with lower dose and titrate upward slowly                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Sulfonylurea (gliclazide, glipizide, glimepiride, glibenclamide)                                                           ↑ Insulin secretion from β-cells                                                                                                                                           Yes                   Yes                                                           1.0--2.0                                                                                                                                                                               Severe hepatic or renal insufficiency, secondary failure
  Before meal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Meglitinide (repaglinide, nateg- linide, mitiglinide)                                                                      ↑ Insulin secretion from β-cells, ↓ postprandial hyperglycemia                                                                                                             Yes                   Yes                                                           0.5--1.5                                                                                                                                                                               Severe hepatic or renal insufficiency
  Before each meal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  DPP4 inhibitor (sitagliptin, vildagliptin, saxagliptin, linagliptin, gemigliptin, alogliptin, teneligliptin, anagliptin)   ↑ Postprandial incretin (GLP-1, GIP), ↑ glucose-dependent insulin secretion, ↓ postprandial glucagon secretion, ↓ postprandial hyperglycemia, use regardless of mealtime   No                    No                                                            0.5--1.0                                                            Angioedema, urticaria                                                                                              Dose titration in severe hepatic or renal insufficiency
  Acute pancreatitis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Risk for heart failure (saxagliptin, alogliptin)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Thiazolidinedione (pioglitazone, lobeglitazone)                                                                            ↑ Insulin sensitivity (muscle, adipose tissue), ↓ hepatic glucose production, once daily regardless of mealtime                                                            Yes                   No                                                            0.5--1.4                                                            Edema, anemia, bone fracture, heart failure                                                                        Heart failure, severe hepatic or renal insufficiency
  SGLT2 inhibitor (dapagliflozin, ipragliflozin, empagliflozin)                                                              ↓ Renal glucose reabsorption, ↑ glucosuria                                                                                                                                 No                    No                                                            0.5--1.0                                                            Genitourinary tract infections, polyuria, dehydration, DKA                                                         Old age, heart failure, hypotension, diuretics use, not for severe CKD (eGFR \< 60 mL/min/1.73 m^2^)
  Once daily regardless of mealtime                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  α-Glucosidase inhibitor (acarbose, voglibose)                                                                              ↓ Upper intestinal glucose absorption, ↓ postprandial hyperglycemia                                                                                                        No                    No                                                            0.5--1.0                                                            GI side effects (flatulence, diarrhea, bloating)                                                                   Severe hepatic or renal insufficiency, chronic inflammatory bowel disease with malabsorption, severe infection
  Before each meal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

Adapted Ko et al. \[[@b11-kjim-2017-312]\].

HbA1c, glycosylated hemoglobin; GI, gastrointestinal; eGFR, estimated glomerular filtration rate; DPP4, dipeptidyl peptidase 4; GLP-1, glucagon-like peptide 1; GIP, gastric inhibitory polypeptide; CKD, chronic kidney disease; SGLT2, sodium-glucose cotransporter 2; DKA, diabetic ketoacidosis.

Monotherapy.
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